Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.
Trial collaboration with Netherlands Cancer Institute (NKI); Roche supplies atezolizumab (Tecentriq).
Second pharma-funded LB-100 immunotherapy trial; earlier GSK trial for clear cell ovarian cancer started 2024.
Aims to bring immunotherapy to ~85% of colorectal cancer patients currently unresponsive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.